Øystein Rekdal
Overview
Øystein Rekdal is a Norwegian entrepreneur and investor specializing in the biotech and technology sectors. He co-founded Lytix Biopharma, a clinical-stage biotech company developing novel cancer immunotherapies, and has served as its CEO since 2019. Under his leadership, Lytix Biopharma has advanced its pipeline of oncolytic peptides aimed at personalizing immunotherapy treatments. Dr. Rekdal holds a PhD from the University of Tromsø, focusing on cytokines and tumor immunology. He has an extensive research background in peptide chemistry, biochemistry, and tumor biology, and has been instrumental in developing the company's peptide platform. He also serves as a professor at the Medical Biochemistry Department in the Faculty of Medicine at the University of Tromsø, collaborating with several distinguished international institutions. In addition to his role at Lytix Biopharma, Dr. Rekdal has been involved in various initiatives to promote Norway's health industry, emphasizing the potential for growth and international collaboration in the sector. His expertise and leadership have been recognized in the biotech community, contributing to the advancement of innovative cancer therapies.
Investment Focus
- Innovative biotech startups
- Strong scientific research foundation
- Potential for international collaboration
Portfolio Companies
Reach Øystein Rekdal directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Øystein Rekdal
What sectors does Øystein Rekdal invest in?
Øystein Rekdal invests in Healthcare and Biotechnology, and is based in Oslo, Norway. Øystein Rekdal is listed as a angel investor in the ConnectSafely investor database.
What stage does Øystein Rekdal invest at?
Øystein Rekdal backs companies at Seed and Early Stage, writing cheques of 1M - 5M.
Which regions does Øystein Rekdal invest in?
Øystein Rekdal invests across United States and Norway.
What companies has Øystein Rekdal invested in?
Øystein Rekdal's portfolio includes Lytix Biopharma.
Last updated · Source: ConnectSafely investor database
